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The present study was undertaken to clarify the role of Sendai virus (SeV) V protein, which has been shown to downregulate IFN-β induction
through inhibition of IRF-3 activation, in viral pathogenesis. Mice infected with rSeV mutants, deficient in V expression or expressing V lacking
the C-terminus, had several-fold higher IFN activity levels in the lungs than those in wild-type virus-infected mice, and the mutant viruses were
rapidly excluded from the lung from the early phase of infection before induction of acquired immunity. In addition, the unique early clearance of
the mutants did not occur in IRF-3 knockout (KO) mice. However, high titers of IFN were detected even in the infected KO mice. Furthermore,
early clearance of the mutant viruses was also observed in IFN signaling-deficient mice, IFN-α/β receptor KO mice and STAT1 KO mice. These
results indicate that SeV V protein counteracts IRF-3-mediated innate antiviral immunity for efficient virus replication and pathogenesis in mice,
but it is not IFN.
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The subfamily Paramyxovirinae of the family Paramyxo-
viridae includes many human and animal pathogens such as
measles virus as well as the newly emergent Hendra and Nipah
viruses, which can cause fatal zoonotic infections (Lamb and
Kolakofsky, 2001). Viruses are subjected to various antiviral
host responses upon infection, and interferon (IFN) responses
play important roles in early innate immunity and in modulation
of subsequent acquired immunity (Goodbourn et al., 2000; Sen,
2001; Taniguchi and Takaoka, 2002). Recent extensive studies
have revealed that most paramyxoviruses encode specific viral
proteins, accessory V and/or C proteins encoded by the P gene
to circumvent the IFN system by blocking IFN signaling and
limiting the production of IFN in infected cells (Garcia-Sastre,
2001, 2004; Goodbourn et al., 2000; Gotoh et al., 2001, 2002;⁎ Corresponding author. Fax: +81 82 257 5159.
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doi:10.1016/j.virol.2006.08.053Horvath, 2004; Nagai and Kato, 2004). For instance, in simian
virus 5 (SV5), which belongs to the genus Rubulavirus of
Paramyxovirinae, the V protein targets STAT1 for proteasome-
mediated degradation, thereby blocking both IFN-α/β and IFN-
γ signaling within infected cells (Didcock et al., 1999a, 1999b),
while the C protein, instead of the V protein, counteracts IFN
signaling in the case of Sendai virus (SeV) of the genus Re-
spirovirus of Paramyxovirinae (Didcock et al., 1999a, 1999b;
Garcin et al., 1999; Gotoh et al., 1999). SeV C protein blocks
IFN signaling by inducing abnormal phosphorylation and
dephosphorylation of STAT1 and STAT2 and its binding to
STAT1 (Gotoh et al., 2003a, 2003b; Kato et al., 2004; Komatsu
et al., 2000, 2002; Takeuchi et al., 2001). In addition, it has
become evident that V and C proteins downregulate the
production of IFN in infected cells as well. The V proteins of
SV5 and SeV have been shown to inhibit induction of IFN-β
through blocking interferon regulatory factor (IRF)-3 and NF-
κB activation (He et al., 2002; Komatsu et al., 2004; Poole et al.,
2002). SeV C protein also blocks the signaling pathway leading
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helicases, retinoic acid inducible gene I (RIG-I) and melanoma
differentiation-associated gene 5 (mda-5) products, have re-
cently been identified as the host factors for detecting
intracellular dsRNA produced by virus replication and initiating
antiviral responses (Andrejeva et al., 2004; Yoneyama et al.,
2004). In addition, the cysteine-rich C-terminal domain of V
protein, highly conserved among paramyxoviruses, has been
demonstrated to bind mda-5, resulting in inhibition of activation
of the IFN-β promoter through IRF-3 (Andrejeva et al., 2004;
Yoneyama et al., 2005). Thus, the V and C proteins of
paramyxoviruses are thought to play essential roles for evading
host innate immunity, especially the IFN system, upon virus
infection. However, it is still unclear how the inhibitory capacity
of V protein against IRF-3 activation revealed in vitro is
actually involved in in vivo viral replication and pathogenesis.
SeV infects exclusively respiratory epithelial cells of rodents
and causes fatal bronchopneumonia (Ishida and Homma, 1978),
and experimental infection of mice with SeV has provided a
useful model for investigation of viral pathogenesis (Fujii et al.,
2002; Kato et al., 1997a, 1997b; Kiyotani et al., 1990; Kurotani
et al., 1998; Sakaguchi et al., 2003; Tashiro and Homma, 1983).
SeV is an enveloped virus possessing a non-segmented single-
stranded negative-sense RNA genome containing six genes in
the order 3′-(leader)-N-P-M-F-HN-L-(trailer)-5′. The accessory
proteins, V and C, are also expressed from the genome in
infected cells. The V protein is generated from a P gene tran-
script subpopulation possessing an insertion of a nontemplated
G residue at a specific editing site, and hence the V protein
consists of a P/V common amino-terminal half and a V unique
carboxyl-terminal half. The V-unique C-terminal region con-
tains 15 amino acid residues highly conserved among almost all
paramyxoviruses, including 7 cysteine residues that form a zinc
finger-like motif and, indeed, bind Zn2+ (Fukuhara et al., 2002;
Huang et al., 2000; Liston and Briedis, 1994; Paterson et al.,
1995; Steward et al., 1995). On the other hand, C′, C, Y1 and Y2
proteins, collectively called C proteins, are encoded by an
overlapping, shifted open reading frame of the upstream regions
of the P and V mRNAs with multiple translational start codons
and a common termination codon. The C protein is expressed by
viruses belonging to three of the five genera of Paramyxoviri-
nae: Respirovirus, Morbillivirus and Henipahvirus (Lamb and
Kolakofsky, 2001; Nagai, 1999; Nagai and Kato, 2004).
We demonstrated previously by using a reverse genetics
system that SeV Vand C proteins are categorically nonessential
gene products for viral replication but that silencing their ex-
pression severely impairs viral replication and pathogenesis, and
we have suggested that the Vand C proteins function for evading
host innate immunity (Kato et al., 1997a, 1997b; Kurotani et al.,
1998). However, C-knockout (KO) SeV [rSeV C(−)] and V-KO
SeV [rSeV V(−)] were different with respect to their replication
in cultured cells and in the mouse lung: replication of rSeV C(−)
was severely impaired both in cultured cells and in mice,
whereas rSeV V(−) propagated in cultured cells as efficiently as
or more efficiently than the parental wild-type (WT) virus but
showed a unique attenuated replication phenotype in mice. V(−)
virus replicated in the mouse lung as efficiently asWT virus until1 day after infection but was cleared from the lung thereafter far
more rapidly than WT virus, indicating that SeV V protein
encodes a luxury function required for in vivo viral replication
and pathogenesis (Kato et al., 1997a). The pathogenicity deter-
minant in the V protein was mapped to the highly conserved
cysteine-rich C-terminal half (Fukuhara et al., 2002; Huang et
al., 2000; Kato et al., 1997b). The unique characteristics of rSeV
V(−) replication have been confirmed with a highly virulent SeV
field isolate (Sakaguchi et al., 2003). The poor replication
capacity of rSeV C(−) both in cultured cells and in mice could be
explained by the multifunctional capacity of the C protein, with
probable roles in virus assembly (Hasan et al., 2000; Sugahara et
al., 2004) and control of viral transcription (Curran et al., 1992),
in addition to inhibition of IFN signaling. It is unclear, however,
whether the luxury function of SeVV protein required for in vivo
viral replication and pathogenesis can be explained by its
inhibitory effect on IRF-3 activation leading to negative
regulation of IFN-β production because rSeV V(−) can replicate
well even in cultured cells producing IFN, and IRF-3 also
functions as a key activator of multiple cellular genes other than
the immediate early IFN-α/β genes (Grandvaux et al., 2002).
In the present study, we investigated replication and
pathogenesis of rSeV mutants of the V protein in mice
possessing various deficiencies in innate immunity to clarify
roles of the inhibitory capacity of V protein against IRF-3 acti-
vation in virus replication and pathogenesis. The results obtained
indicate that propagation of the rSeV mutants in the mouse lung
is suppressed by a cellular factor(s) induced by IRF-3, but it is
not IFN, and that SeV V protein is required for counteracting
IRF-3-induced innate immunity other than IFN to replicate
efficiently in mice.
Results
Inhibition of rSeV V(−) replication at the early phase of mouse
infection occurs independently of T cell functions
To investigate the involvement of T cell functions in rSeV
V(−) clearance from infected mice, replication of V(−) virus was
examined in T cell-deficient BALB/cnu/nu mice. rSeV WT
propagated efficiently in BALB/c mice and was cleared from the
lung by day 9 post infection (p.i.) (Fig. 1A). In BALB/cnu/nu
mice, WT virus replicated more efficiently than it did in BALB/c
mice, and a high virus load was maintained throughout the
observed infection period (Fig. 1B). In contrast, in BALB/c
mice, V(−) virus began to be cleared from day 2 p.i. in a stepwise
manner and became undetectable on day 7 p.i., though the
infectivity of V(−) virus on the first day p.i. was almost the same
as that of WT virus (Fig. 1A), confirming previous results
obtained in ICR mice (Kato et al., 1997a). In BALB/cnu/nu mice,
rSeV V(−) grew as well as WT virus until the first day p.i. and
then decreased rapidly to approximately 1/1000 of WT virus in
infectivity by day 3 p.i. (Fig. 1B), as was observed in BALB/c
mice. However, infectivity of V(−) virus in the lung began to
increase again from day 5 p.i., and the titers remained thereafter
in the order of 106 cell-infecting units (CIU), less than 1/10 of
that of WT virus. These results indicate that clearance of rSeV
Fig. 1. Time course of rSeV V(−) replication in the lungs of T cell-deficient
nude mice. Four-week-old BALB/c (A) and BALB/cnu/nu mice (B) were in-
fected i.n. with 107 CIU of rSeV WT (open circles) or rSeV V(−) (closed
circles). At the indicated intervals, three mice in each group were sacrificed
and examined for virus replication in the lung. Each value represents the mean±
SE of 3 mice.
Fig. 2. Induction of IFN activity in rSeV V(−)-infected mice. Three-week-old
ICR mice were infected i.n. with 107 CIU of rSeV WT or rSeV V(−), and
virus replication (A) and IFN production (B) in the lung were examined. IFN
activities in the lung homogenates of mice infected with rSeV WT (open bars)
or rSeV V(−) (shaded bars) were measured biologically by titration of antiviral
activity against VSV. IFN-γ produced in the lung infected with rSeV WT
(open circles) or rSeV V(−) (closed circles) was assayed by ELISA. Each
value represents the mean±SE of 3 mice.
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ICR mice occurs independently of T cell functions. It may be
caused by an innate immunity, the activity of which appeared
to peak on day 3 p.i. and persist thereafter at a low level (Fig.
1B), while the virus clearance in BALB/c and ICR mice at the
later phase after day 5 p.i. (Fig. 1A) could be mainly due to
specific adaptive immunity such as cytotoxic T lymphocytes.
Induction of IFN activity in rSeV V(−)-infected mice
Induction of IFN in the lungs of rSeV V(−)-infected ICR
mice was examined by titration of antiviral activity against
vesicular stomatitis virus (VSV) and by ELISA for IFN-γ to
clarify the mechanism underlying the early clearance of V(−)
virus from mice (Fig. 2). On the first day p.i., V(−) virus-
infected mice showed activity levels of type I IFN several-fold
higher than those in the WT virus-infected mice (Fig. 2B, see
also Figs. 5A, C), although almost the same virus infectivities
were detected in lungs of the V(−) and WT virus-infected mice
(Fig. 2A), consistent with the fact that the V protein of SeV
inhibits activation of IRF-3 and IFN-β induction in cells
(Komatsu et al., 2004; Poole et al., 2002). IFN activities then
decreased in the V(−) virus-infected mice in contrast to the
increase in the WT virus-infected mice. This may be a reflection
of the levels of virus propagation in the respective infected
mice. On the other hand, levels of IFN-γ titers produced in the
V(−) virus-infected mice were similar to or lower during the
course of infection than those in the WT virus-infected mice
(Fig. 2B). V(−) virus showed essentially the same replication
pattern in BALB/c-IFN-γ−/− mice as that in BALB/c mice (data
not shown). These results suggest that the observed early
clearance of SeV V(−) from the mouse lung might be caused bythe unusual strong induction of type I IFN and/or NK cell
activities at the early phase of V(−) virus infection.
Replication of rSeV V(−) in NK cell-deficient beige mice
rSeV V(−) showed the unique early poor replication pattern
even in C57BL/6bg/bg mice (Fig. 3B) as in C57BL/6 mice (Fig.
3A), although cytocidal activity of NK cells was deficient under
the condition of SeV infection in the beige mice (Fig. 3C). The
results indicate that the early clearance of V(−) virus from the
mouse lung is independent of NK cell activity.
Replication and pathogenesis of rSeV V(−) and rSeV VΔC in
IRF-3 KO mice
Since SeV V protein inhibits IRF-3 activation and IFN-β
induction in infected cells, replication and pathogenesis of
rSeV V(−) and rSeV VΔC (an SeV mutant expressing the V
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ed in IRF-3 KO mice to determine the involvement of IRF-3 in
the early clearance of V mutant viruses from the lung. In the
control C57BL/6J mice, rSeV V(−) and rSeV VΔC showed
essentially the same early clearance phenotype as that
observed in ICR, BALB/c and C57BL/6 mice (Fig. 4A),
although rSeV VΔC was cleared from the lung more slowly
than rSeV V(−), consistent with previous results obtained in
ICR mice (Kato et al., 1997b). In C57BL/6J-IRF-3−/− mice,
rSeV WT appeared to replicate more efficiently than it did in
the control mice (Figs. 4A and B). Furthermore, in marked
contrast to the control mice, both V(−) and VΔC viruses also
propagated very efficiently in the KO mice and their unique
early clearance phenotype was not observed (Fig. 4B). V(−)
virus appeared, however, to show slightly less replication after
5 days p.i. than that of WT virus even in the KO mice, while
VΔC virus replicated as well as WT virus (Fig. 4B).
Pathogenicity of the WT and V mutant viruses to mice,
examined by mouse body weight loss and lung consolidation,
paralleled well the respective virus replication ability in C57BL/
6J and C57BL/6J-IRF-3−/− mice. Both V(−) virus-infected and
VΔC virus-infected C57BL/6J mice showed less body weight
loss and lung consolidation than those of WT virus-infected
mice, although weight loss and lung consolidation of VΔC virus-
infected mice were slightly greater than those of V(−) virus-
infectedmice (Fig. 4A). On the other hand, in the KOmice, V(−)
virus and VΔC virus infection resulted in large degrees of body
weight loss and lung consolidation similar to those caused by
WT virus, and all of the infected mice died within the
observation period (Fig. 4B). Table 1 shows comparisons of
LD50s of WT, V(−) and VΔC viruses in C57BL/6J mice and
those in C57BL/6J-IRF-3−/− mice. The LD50s of V(−) and VΔC
viruses in C57BL/6J mice were 184-fold and 100-fold higher,
respectively, than that of WT virus, while in the KO mice, LD50
of V(−) virus was 37-fold higher than that of WT virus and VΔC
virus showed exactly the same LD50 as that of WT virus.Fig. 3. Replication of rSeV V(−) in NK cell-deficient beige mice. Five-week-old C57
rSeVWT (open circles) or rSeV V(−) (closed circles), and viral infectivities in the lun
was measured in the C57BL/6 (closed triangles) and beige mice (open triangles) in
against YAC-1 target cells, and specific cytotoxicity (%) was determined at an R/TThese results indicate that a certain gene product induced by
IRF-3, including IFN-β, is involved in the early clearance of SeV
V(−) and SeV VΔC from the lung and viral pathogenesis and also
that VΔC virus, but not V(−) virus, possesses the capacity to
replicate as efficiently as WT virus in IRF-3 KO mice.
Production of IFN in IRF-3 KO mice infected with SeV
To confirm the absence of induction of IFN through IRF-3
activation, type I IFN production was examined in C57BL/6J-
IRF-3−/− mice infected with rSeV WT or rSeV V(−) (Fig. 5). In
the control C57BL/6J mice infected with WT or V(−) virus,
essentially the same results as those shown in Fig. 2 were
obtained (Fig. 5A). However, high titers of IFN activity were
also detected in the WT virus- or V(−) virus-infected IRF-3 KO
mice (Fig. 5D), although kinetics of IFN induction was
significantly different from that in C57BL/6J mice. The IFN
activity in WT virus-infected KO mice peaked on day 2 p.i. and
disappeared by day 7 p.i., while the peak of IFN activity in
infected C57BL/6J mice was on day 3 p.i. and high titers of the
activity were detected until day 7 p.i. In addition, unusual strong
induction of IFN activity in the V(−) virus-infected C57BL/6J
mice on day 1 p.i. compared with that in the WT virus-infected
mice was not observed in the KO mice. When IFN-α/β were
measured by ELISA, both peaks of IFN-α and IFN-β were on
day 2 p.i. in the WT or V(−) virus-infected IRF-3 KO mice
(Figs. 5E, F), while in the WT virus-infected C57BL/6J mice,
the peaks of IFN-β and IFN-α were on day 1 p.i. and day 3 p.i.,
respectively (Fig. 5B). In the V(−) virus-infected C57BL/6J
mice, both peaks of IFN-β and IFN-α were on day 1 p.i., and
the titer of IFN-β was several-fold higher than that in the WT
virus-infected mice (Fig. 5C). Subsequent increase in IFN-α
was not detected in the V(−) virus-infected C57BL/6J mice.
These results suggest that the IFN-α/β detected in the KO mice
are produced through a pathway other than IRF-3-mediated
signal transduction. It is possible that IFN was induced throughBL/6 (A) and C57BL/6bg/bg (beige) (B) mice were infected i.n. with 107 CIU of
g were assayed at various time points after infection. Splenic NK cell activity (C)
fected with 107 CIU of rSeV WT using the standard 51Cr-release assay method
ratio of 50:1. Each value represents the mean±SE of 3 mice.
Table 1
LD50s of rSeV mutants in IRF-3 KO mice
Virus LD50 (CIU/mouse) in
C57BL/6J C57BL/6J-IRF-3−/−
rSeV WT 3.2×105 (1) 1.5×104 (1)
rSeV V(−) 5.9×107 (184) 5.6×105 (37)
rSeV VΔC 3.2×10
7 (100) 1.5×104 (1)
The numbers in parentheses are ratios of LD50 of rSeV V(−) and rSeV VΔC to
that of rSeV WT in C57BL/6J or C57BL/6J-IRF-3−/− mice.
Fig. 4. Replication and pathogenicity of rSeV V(−) and rSeV VΔC in IRF-3 KO
mice. Five-week-old C57BL/6J (A) and C57BL/6J-IRF-3−/− mice (B) were
infected i.n. with 107 CIU of rSeV WT, rSeV V(−) or SeV VΔC. The mice were
weighed daily, and 2 or 3 mice in each group were sacrificed at the indicated
intervals and examined for lung consolidation and virus infectivity in the lung.
Each circle shows one mouse and + indicates a mouse that died.
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expressed in plasmacytoid dendritic cells (pDCs) in the mice
(Honda et al., 2005; Izaguirre et al., 2003). We therefore
examined IFN induction in cultures of primary mouse fibroblast
cells derived from C57BL/6J and C57BL/6J-IRF-3−/− mice, in
which pDCs were absent. As shown in Table 2, neither IFN-β
nor IFN-α was detected in the cultures of cells derived from theIRF-3 KO mouse upon infection with WT or V(−) virus, in
contrast to production of significant amounts of IFN-α/β in the
cell cultures from C57BL/6J mice. These results indicate that
high titers of type I IFN are produced even in the IRF-3 KO
mouse by SeV infection, probably through IRF-7 activation in
pDCs, thus suggesting that IFN might not account for the early
clearance of SeV V mutants from the mouse lung.
Replication of rSeV V(−) in mice deficient in IFN signal
transduction
To further investigate whether the strong induction of type I
IFN observed in rSeV V(−)-infected mice is directly involved
in the virus clearance at the early phase of infection, virus
replication in the lung was examined in IFN signal transduction-
deficient mice, IFN-α/β receptor KOmice and STAT1KOmice.
V (−) virus showed the unique early clearance phenotype even in
IFN-α/β R−/− (A129) mice, similar to that in 129/Sv mice (Fig.
6). Essentially the same results were also obtained in STAT1−/−
mice (data not shown). These results, together with the results
described in the preceding section, indicate that IFN-α/β is not a
main effector for the early clearance of V(−) virus from the
mouse lung and suggest that a certain factor, other than IFN-β,
induced through IRF-3 activation is involved in the early virus
clearance.
Discussion
In the present study, we investigated the replication and
pathogenesis of SeVVmutants, rSeVV(−) and rSeVVΔC, using
mice with various deficiencies in innate immunity to clarify the
in vivo significance of the inhibitory capacity of V protein
against IRF-3 activation, particularly whether IFN is directly
involved in the clearance of the SeVmutants from the lung at the
early stage of infection. Consistent with the prediction by results
obtained in vitro showing suppression of IFN-β induction
through inhibition of IRF-3 activation by the V protein (He et al.,
2002; Komatsu et al., 2004; Poole et al., 2002), a several-fold
higher level of IFN was actually produced on day 1 p.i. in the
rSeV V(−)-infected mouse lung compared with that in the WT
virus-infected mice (Figs. 2 and 5A, C). In addition, early
clearance of the SeVmutants did not occur in the IRF-3 KOmice
(Fig. 4), suggesting that IFN induced through IRF-3 activation
may account for the early clearance of the virus mutants.
However, high titers of IFN-α/β, probably produced from pDCs
through the TLR9/7-Myd88-IRF-7 pathway (Honda et al.,
2005), were detected on day 2 p.i. even in the IRF-3 KO mice
Fig. 5. IFN production in IRF-3 KOmice infected with SeV. Five-week-old C57BL/6J (A, B, C) or IRF-3−/−mice (D, E, F) were infected i.n. with 107 CIU of rSeVWT
or rSeV V(−), and IFN induction in the lung at various time points after infection was determined. (A, D) IFN activities in the lung were titrated biologically after
infection with rSeV WT (open circles) or rSeV V(−) (closed circles). Each value represents the mean±SE of 2 or 3 mice. (B, E) IFN-α (closed triangles) and IFN-β
(open triangles) in the WT virus-infected mouse lung were assayed by ELISA. (C, F) IFN-α (closed triangles) and IFN-β (open triangles) in the V(−) virus-infected
mouse lung were also assayed by ELISA.
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SeV mutants were able to replicate almost normally (Fig. 4B).
Furthermore, early clearance of the SeV mutants was also
observed in mice deficient of IFN signal transduction, IFN-α/β
receptor KO mice (Fig. 6) and STAT1 KO mice. These results
indicate that the host factor responsible for the early clearance of
the SeV mutants is expressed through activation of IRF-3 but
that it is not IFN. Therefore, the major role of SeVV protein in in
vivo viral replication and pathogenesis is thought to be
counteraction of a certain antiviral innate immunity other than
IFN induced by IRF-3 rather than inhibition of IFN production,Table 2
IFN production in rSeV WT or rSeV V(−)-infected primary fibroblast cultures
prepared from C57BL/6J and C57BL/6J-IRF-3−/− mice
Cells Infected
with
IFN production (pg/ml)
IFN-α IFN-β
C57BL/6J WT 450 560
V(−) 420 1400
IRF-3−/− WT <1 <1
V(−) <1 <1
Monolayers of primary mouse fibroblasts prepared from C57BL/6J or C57BL/
6J-IRF-3−/− mice were infected with rSeV WT or rSeV V(−) at an m.o.i. of
approximately 10, and IFN-α and IFN-β in the medium at 24 h p.i. were assayed
by ELISA.but the possibility of involvement of IFN and NK cells in the
early clearance of the virus mutants as indirect or supplementary
effectors could not be ruled out. Although the IFN response
seems not to be important in controlling early SeV replication in
vivo, it should be noted that the SeV V mutants used still have
functional C proteins to help counter the IFN response.Fig. 6. Replication of rSeV V(−) in the lung of IFN-α/β receptor KO mice. Six-
to seven-week-old IFN-α/β R−/− (A129) mice and their parent 129/Sv mice
were infected i.n. with 107 CIU of rSeVWT (open circles) or rSeV V(−) (closed
circles), and viral infectivities in the lung were measured at the indicated time
points after infection. Each point shows one mouse.
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replication ability and pathogenicity than those of rSeV VΔC in
the IRF-3 KO mice (Fig. 4B and Table 1), it is likely that the
IFN-γ produced in the infected mice (Fig. 2) accounts for the
difference between the mutant viruses. rSeV VΔC might be able
to propagate in the KO mice as efficiently as WT virus by anti-
IFN-γ activity of the N-terminal P/V common fragments of V
protein, which were expressed in the VΔC virus-, but not the
V(−) virus-, infected cells since the N-terminal P/V common
fragments, but not the C-terminal V unique fragments,
constitutively expressed in HeLa cells showed significant
inhibitory activities against antiviral effects of IFN-γ (A.
Kato, unpublished data), although the V protein and its P/V
common and V unique fragments did not show any anti-IFN-α/
β activity (Kato et al., 2004). This view is also supported by the
observation of lower replication of V(−) virus after day 5 p.i. in
the KO mice (Fig. 4B), compared to that of VΔC virus, when
significant IFN-γ production was induced.
The present study suggested that expression of the host
factor responsible for the early clearance of the SeV V
mutants from mice is closely related to the functions of IRF-3
other than the induction of IFN-β. Many IFN-stimulated
responsive element (ISRE)-containing genes are induced in
response to virus infection without the need for prior de novo
IFN synthesis (Grandvaux et al., 2002; Nakaya et al., 2001;
Nicholl et al., 2000). IRF-3 is ubiquitously present in a latent
form in the cytoplasm of uninfected cells and upon
stimulation mediates gene transcription through recognition
of ISRE sequences. Thus, IRF-3 is considered a potential
candidate to regulate IFN-stimulated genes (ISGs) in the early
events of innate response to virus infection. It has been
reported that activated IRF-3 transcriptionally upregulates the
chemokine genes RANTES and IP-10 (Lin et al., 1999;
Nakaya et al., 2001), and other ISGs, such as ISG15, ISG54,
ISG56, ISG60, Arg II, GBP1 and CIG5 (Grandvaux et al.,
2002; Nakaya et al., 2001), in addition to IFN-β. Among
these, ISG15 (Lenschow et al., 2005; Ritchie et al., 2004),
GBP1 (Anderson et al., 1999) and CIG5 (Chin and Cresswell,
2001) gene products have been demonstrated to possess
antiviral activity. Furthermore, IRF-3 plays a role in
mediating SeV-induced apoptosis (Heylbroeck et al., 2000).
It has recently been shown that the Arg II gene product
(arginase II) participates in the IFN-independent antiviral
response through polyamine production and induction of
apoptosis (Grandvaux et al., 2005). Involvement of arginase II
in the early clearance of the SeV V mutants through apoptosis
induction, however, seems unlikely because V(−) virus was
able to propagate in cultured cells as efficiently as or more
efficiently than WT virus, although enhanced cytopathic
effects (CPE), possibly due to apoptosis, were actually
observed in the cells (Kato et al., 1997a). The host factor
responsible for the early clearance of the SeV mutants
expressed through IRF-3 activation remains to be elucidated.
The mechanism underlying the luxury function of SeV V
protein, which is required for viral replication and pathogenesis
in vivo but not in cultured cells, is still enigmatic. The host
factor responsible for the early clearance of the SeV V mutantsmight be expressed in cells present only in mice, such as
macrophages and DCs, through IRF-3 activation but not in
usual cell lines. Alternatively, since V(−) virus propagated as
well as WT virus until 1 day after infection in the mouse lung
(Fig. 1), a host factor other than IFN-β expressed through IRF-3
activation by virus infection might trans-activate some cells
present only in mice to exert antiviral activity or to produce
another host factor for the innate virus clearance.
Studies on SeVaccessory proteins Vand C, together with the
present study, have shown that the V and C proteins play
important roles in evading host innate immunity cooperatively.
SeV V and C proteins might have differentiated to counteract
the unknown IRF-3-mediated innate immunity and the IFN
system, respectively, from the common ancestral V protein of
paramyxoviruses possessing both anti-IRF-3 and anti-IFN
signaling activities such as SV5 V protein. The function of
SeV V protein revealed in the present study has been shown
only with SeV at present, but it is possible that other
paramyxovirus V proteins also possess such a function since
the V-unique C-terminal half responsible for counteracting the
early clearance of SeV from mice is highly conserved among
paramyxoviruses, and all of the paramyxovirus V proteins of
SV5, human parainfluenza virus 2, mumps virus, Hendra virus
as well as SeV have been shown to inhibit IRF-3 activation
through binding to mda-5 (Andrejeva et al., 2004). Studies on
the V protein of SeV, for which an experimental animal model is
available, will shed light on innate immunity against virus
infection.
Materials and methods
Cells and viruses
LLC-MK2, Vero, BHK-21 and L cells were grown in Eagle's
MEM supplemented with 10% bovine serum (BS). NK cell-
sensitive YAC-1 cells, derived from Moloney murine leukemia
virus-induced lymphoma in an A/Sn mouse, were grown in
Iscove-modified DMEM supplemented with 10% FCS. Primary
mouse fibroblast cells were prepared from 1- or 2-day-old
newborn C57BL/6J or C57BL/6J IRF-3−/− mice by trypsiniza-
tion and grown in DMEM supplemented with 10% FCS.
rSeV WT and its mutant viruses rSeV V(−) and rSeV VΔC
recovered from cDNAs (Kato et al., 1996, 1997a, 1997b) were
used in the present study, and they were propagated in 11-day-
old embryonated chicken eggs. Infectivity was measured by an
immunofluorescent cell-counting assay using LLC-MK2 cells
as host cells and expressed as CIU per ml (Kiyotani et al., 1990).
VSV-NJ strain was grown in BHK-21 cells, and the infectivity
was measured by the tissue culture 50% infectious dose
(TCID50) method using L cells.
Infection of animals
Three-week-old male ICR mice, 4-week-old male BALB/c
and BALB/cnu/nu (nude) mice and 5-week-old male C57BL/6
and C57BL/6bg/bg (beige) mice were purchased from Charles
River Japan, Inc. (Atsugi, Japan). Six- to seven-week-old male
89K. Kiyotani et al. / Virology 359 (2007) 82–91IFN-α/β R−/− mice (A129) and their parent mice (129/Sv) were
purchased from B&K Ltd. (East Yorkshire, UK). Four- to six-
week-old BALB/c-IFN-γ−/− mice were kind gifts from Dr.
Yoichiro Iwakura (The Institute of Medical Sciences, The
University of Tokyo, Japan). Five-week-old male STAT1−/−
mice (Taconic 002045-M) and their parent mice 129S6 (Taconic
129SVE) were purchased from Taconic Quality Laboratory
Animals and Service for Research (Petersburg, NY). Mating
pairs of C57BL/6J-IRF-3−/− mice (No. 00858) were purchased
from RIKEN Bioresource Center (Ibaraki, Japan), and the
offspring of both sexes were used for experiments at the age of 5
weeks. Five-week-old C57BL/6J mice were purchased from
CREA Japan Inc. (Tokyo, Japan) and used as background
controls of IRF-3 KO mice. Deficiency of IFN-α/β receptor in
A129 mice was indirectly checked by unresponsiveness of
primary lung cells, derived from A129 mice, to IFN treatment
for protection of the cells from VSV challenge (data not shown).
Lack of STAT1 expression in the STAT1−/− mice was confirmed
by Western blotting using an anti-STAT1 antibody (data not
shown). Deficiency of IRF-3 expression in the IRF-3−/− mice
was also confirmed by Western blotting using an anti-IRF-3
antibody (data not shown).
All of the mice used were specific pathogen-free and were
kept under bioclean and regulated conditions in the BSL3
facility in the Institute of Laboratory Animal Science, Division
for Research Support, Life Science Center, Hiroshima Univer-
sity. All animal experiments complied with the guidelines set by
the Institute of Laboratory Animal Science, Hiroshima
University. Each mouse was infected intranasally (i.n.) with a
25-μl inoculum containing viruses of 107 CIU under anesthe-
tization with inhalation of ether and/or i.p. injection of
Nembutal. Infected mice were checked daily for body weight
and clinical signs, and at intervals, some of them were sacrificed
for investigation of lung consolidation, virus replication and
IFN production in the lung, and NK cell activity of splenic
lymphocytes. Lung consolidation was graded from 1 to 4
according to the extent of macroscopic lung lesion, and one
point was added when the mouse died (Kato et al., 1997a). Virus
replication in the mouse lung was determined according to the
method described previously (Kiyotani et al., 1990). LD50s of
rSeV WT, rSeV V(−) or rSeV VΔC were determined as
described previously (Kiyotani et al., 1990). Five mice in a
group of 5-week-old C57BL/6J or C57BL/6J-IRF-3−/− mice
were infected i.n. with various doses of respective SeV and
observed for 2 weeks, and LD50s were then calculated by the
method of Reed and Muench.
IFN assay
IFN activities of SeV-infected mouse lung homogenates
were determined biologically according to the method described
previously (Kiyotani et al., 1990). IFN-α, IFN-β and IFN-γ
were measured by ELISA using a Mouse Interferon Alpha
ELISA kit, Mouse Interferon Beta ELISA kit (PBL Biomedical
Laboratories, Piscataway, NJ) or Mouse IFN-γ Immunoassay
kit (R&D Systems, Minneapolis, MN) according to the
manufacturer's instructions.Assay of NK cell activity
NK cell activities of SeV-infected mouse splenic lympho-
cytes were measured using the standard 51Cr-release assay
method against YAC-1 target cells as described previously
(Kiyotani et al., 1990), and the specific cytotoxicity (%) at an
E/T ratio of 50:1 was determined.
Western blotting analysis of IRF-3 and STAT1
Western blotting was performed as described previously
(Sakaguchi et al., 1999) with some modifications. Liver
emulsions were prepared from 5-week-old C57BL/6J-IRF-3−/−
or C57BL/6J mice, resolved by SDS-PAGE using a 10% gel, and
transferred onto a polyvinylidene difluoride membrane (Amer-
sham Biosciences, Piscataway, NJ). The membrane was probed
with an anti-IRF-3 antibody (sc-9082; Santa Cruz Biotechnology,
Santa Cruz, CA) or an anti-actin antibody (MAB1501; Chemicon,
Temecula, CA) for an internal control and subsequently with
peroxidase-conjugated anti-mouse IgG antibody followed by
visualization with an ECL Advance Western Blotting Detection
System (Amersham Biosciences). For detection of STAT1, spleen
emulsions were prepared from 5-week-old STAT1−/− or 129S6
mice, and the protein-blotted membrane was probed with an anti-
STAT1 antibody (sc-346; Santa Cruz Biotechnology).
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